"The U.S. Food and Drug Administration today approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain.
Opioids are a class of drugs that are used to treat and manage pain. A comm"...
(Generic versions may still be available.)
TRITEC (ranitidine bismuth citrate) Tablets contain a complex of ranitidine, trivalent bismuth, and citrate. Chemically, ranitidine bismuth citrate is N-2-[5-Dimethylaminomethyl-2-furanylmethylthio]ethyl-N'- methyl-2-nitroethenediamine 2-hydroxy-1,2,3- propanetricarboxylate, bismuth (III). Analysis shows that ranitidine bismuth citrate is substoichiometric in ranitidine and citrate.
Ranitidine bismuth citrate is a white to off-white amorphous powder. The approximate molecular formula is [C13H22N4O3S] 0.84 Bi[ C6H5O7] 0.94, and the approximate molecular weight is 651. It is readily soluble in water. Each TRITEC (ranitidine bismuth citrate) Tablet for oral administration contains 400 mg of ranitidine bismuth citrate, equivalent to approximately 162 mg of ranitidine (base), 128 mg of trivalent bismuth, and 110 mg of citrate. Each aqueous film-coated tablet also contains the inactive ingredients FD&C Blue No. 2 Aluminum Lake, magnesium stearate, methylhydroxypropylcellulose, microcrystalline cellulose, Povidone K30, sodium carbonate (anhydrous), titanium dioxide, and triacetin.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Tritec Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.